Signobio Inc.
Paoli, PA Doing business as Sino Biological US Inc.
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Website
- sinobiological.com
- Founded
- 2007
- Employees
- 251-1K
- Estimated annual revenue
- $50M-$100M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | $0 |
| FY2025 | $0 |
| FY2024 | $134,949 |
| FY2023 | $314,550 |
Contract awards
Latest 5 listed here. See the rest on GovTribe.
Similar vendors
About the company
Sino Biological US Inc. is a foreign-owned, self-certified small disadvantaged business located in Chesterbrook, Pennsylvania, specializing in the manufacture of biological goods, particularly recombinant proteins, antibodies, and related scientific materials. Registered in SAM.gov since July 30, 2019, with registration valid through October 30, 2025, the company is structured as a for-profit corporate entity that has established itself as a key provider of biological research materials to various federal agencies. The company focuses on producing high-quality biological products that support critical scientific research, particularly in viral disease prevention, drug development, and emerging pathogen studies.
Through its federal contract awards, Sino Biological US Inc. has consistently provided specialized biological materials and services to multiple prominent federal agencies, including the Centers for Disease Control and Prevention (CDC), National Institutes of Health (NIH), National Cancer Institute, and National Institute of Allergy and Infectious Diseases. The company's contracts have encompassed protein production for candidate vaccine viruses, scale and antibody production, hybridoma cell line generation, and specific viral antigen development. Notable contract work includes generating monoclonal antibodies targeting viral proteins, producing spike proteins for coronavirus research, and supporting antiviral drug development efforts. Most of its contracts have been firm fixed-price purchase orders ranging from $24,700 to $249,050, with no specific set-aside designations in most cases. The company has also been a sub-contractor for organizations like Diazyme Laboratories Inc., Mriglobal, and The Johns Hopkins University, further demonstrating its versatility in providing specialized biological research materials.
Quick answers
Is Signobio Inc. registered in SAM.gov?
Yes. Signobio Inc.'s SAM.gov registration is active through October 29, 2027.
What is Signobio Inc.'s CAGE code?
Signobio Inc.'s CAGE code is 8D9V2, and its Unique Entity ID (UEI) is GVLNLKK92321.
How much has Signobio Inc. received in federal contracts?
Federal contracts obligated $449,499 to Signobio Inc. in fiscal years 2023 through 2027.
What is Signobio Inc.'s most recent federal award?
Signobio Inc.'s most recent federal contract award is Protein production for CVV (75D30124P19805), from CDC Pittsburgh, on September 28, 2024.
On GovTribe
See Signobio Inc.'s full federal record
- Federal contract awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors